Take a fresh look at your lifestyle.

View from India: 2-DG, India’s first anti-Covid drug, comes to hospitals

2-DG will be available in hospitals this month, while the state vaccination program will receive a boost as nearly 120 million vaccines become available, as indicated by the Ministry of Health.

About half of the Covid-19 vaccines will be made available free of charge, with ministry data indicating that about 210 million doses were administered as part of the vaccination campaign.

The Russian vaccine Sputnik V arrived in India last month with Dr. Reddy’s Laboratories in Hyderabad as a marketing department. The Apollo hospitals in Hyderabad have started administering Sputnik V on a trial basis.

This week, the country received three million doses of Sputnik V, weighing 56.6 tons, making it the largest vaccine import shipment to India.

The Apollo Group of Hospitals will administer it in its hospitals across the country. Named after the first Soviet space satellite, Sputnik V is a two-dose vaccine; it’s likely that the single-dose Sputnik Light will soon land on Indian shores as well.

As for other foreign vaccines, US drug makers such as Moderna and Pfizer are in talks with the Indian government, demanding compensation from the government. Currently, Covishield and Covaxin are the vaccines administered in India.

The gap between the two doses of the Covishield vaccine, developed by the University of Oxford and pharmaceutical company AstraZeneca and manufactured by the Pune-based Serum Institute of India, has been reviewed and widened by the Covid-19 Working Group, from the first six to eight weeks to 12-16 weeks.

The first dose of Covishield has been scientifically proven to provide approximately 12 weeks of immunity. However, since Covaxin is not supported by comparable medical findings, the four to six week interval between the two shots remains the same.

Covaxin is a home grown vaccine developed by Bharat Biotech International Ltd of Hyderabad in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

It is hoped that the Covid curve will flatten in the coming months and gradually give way to international travel. Vaccine passports have yet to be made mandatory internationally, but a stamp of approval is a prerequisite.

The AstraZeneca vaccine is approved by the World Health Organization (WHO) and the European Medicines Agency. For its part, Bharat Biotech has applied for the WHO Emergency Use Listing.

Regulatory approval is expected in the coming months. The company is seeking regulatory approvals in more than 60 countries, including the US, Brazil and Hungary.

An anti-Covid drug is expected to be commercially available this month. 2-DG, or 2-deoxy-D-glucose, an anti-Covid drug, is the first of its kind in India developed to stop the virus from multiplying.

It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. The drug is designed for selective accumulation in virally infected cells.

The oxygen crisis led to a sharp increase in the number of fatalities during the second wave. With 2-DG, the patient’s dependence on supplemental oxygen is reduced and the patient’s hospital stay is expected to be shortened.

A recycled drug, 2-DG comes in a powder form that is taken orally by dissolving it in water. It is sold in pouches.

2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences, a laboratory of the Defense Research and Development Organization, in collaboration with Dr. Reddy’s Laboratories.

It is approved by the Drugs Controller General of India. According to media reports, the investigation into the drug began last April. Laboratory experiments have established that the molecule is effective against the SARS-CoV-2 virus and inhibits viral growth.

A higher proportion of 2-DG-treated patients showed RT-PCR negative conversion in Covid-19 patients. This led to the clinical trials of 2-DG, which have proved beneficial.Prime Minister Narendra Modi has praised frontline workers.

The Prime Minister shared his thoughts on Mann Ki Baat, the monthly radio program, saying that India produced 900 tons of liquid medical oxygen daily; now its production has been increased by more than 10 times. Currently, about 9,500 tons are produced every day.

Mold – black and white – is a deadly outcome of the pandemic. The fungal infections are new developments that have occurred in second wave Covid-19 patients.

While there was previously black mold or mucormycosis, it has increased due to the Covid-19 pandemic.

Black fungus, so called because it blackens tissue, can affect the face, infect the nose, eye orbit, or brain, even leading to vision loss.

Patients who also have diabetes and have a low immune system are susceptible to black mold. Meanwhile, reports of white mold or candida albicans have made headlines.

This can damage the lungs, digestive tract, kidneys and brain. It can be more dangerous than the black version as it is believed to spread more quickly to the vital organs of the body.

Patients with low immunity, or those who use steroids or come into contact with water or unsanitary conditions, are prone to white mold. Both black and white yeast infections can be treated with antifungal medications.

dr. Union health minister Harsh Vardhan has informed the media that the country will be equipped to vaccinate at least the entire adult population by the end of the year.